0001213900-24-031700.txt : 20240409 0001213900-24-031700.hdr.sgml : 20240409 20240409204930 ACCESSION NUMBER: 0001213900-24-031700 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240405 FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shakil Ian CENTRAL INDEX KEY: 0001826129 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40890 FILM NUMBER: 24834013 MAIL ADDRESS: STREET 1: C/O AUGMEDIX, INC. STREET 2: 1161 MISSION STREET, SUITE LL CITY: SAN FRANCISCO STATE: CA ZIP: 94103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 4 1 ownership.xml X0508 4 2024-04-05 0 0001769804 Augmedix, Inc. AUGX 0001826129 Shakil Ian C/O AUGMEDIX, INC. 111 SUTTER STREET, SUITE 1300 SAN FRANCISCO CA 94104 1 1 0 0 CHIEF STRATEGY OFFICER 1 Common Stock 2024-04-05 4 S 0 51387 4.0328 D 12217 D Common Stock 2024-04-08 4 M 0 28563 0.64 A 40780 D Common Stock 2024-04-08 4 S 0 28563 3.9695 D 12217 D Common Stock 2024-04-08 4 S 0 9217 3.9695 D 3000 D Stock Option (Right to Buy) 0.64 2024-04-08 4 M 0 28563 0 D 2030-06-03 Common Stock 28563 14356 D This transaction was executed pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades ranging from $3.9400 to $4.1700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Fully vested. /s/ Todd Holvick, Attorney-in-Fact 2024-04-09